Inhibition of MCL1 reduces AML in an in vivo murine model.

Slides:

Advertisements

Similar presentations

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

Advertisements

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Fig. 1 Increasing UCB cell dose impairs short-term progenitor cell engraftment. Increasing UCB cell dose impairs short-term progenitor cell engraftment.

In vivo responses of AMLMLL to ATRi.

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative.

PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice Denis R. Burger, Yvonne Parker, Kathryn.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

RUNX transcription factors potentially control E-selectin expression in the bone marrow vascular niche in mice by Ken Morita, Chieko Tokushige, Shintaro.

Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells by Xiaoli Wang, Cing Siang Hu, Bruce Petersen, Jiajing.

VAY-736 combines effectively with ibrutinib in vivo.

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras by S. Haihua Chu, Evelyn J. Song,

CXCR5 expression accelerates Eμ-Tcl1 leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. CXCR5 expression accelerates.

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

Activity of MAC-321 (i. v. and p. o

Decreased expression of cell cycle– and apoptosis-related genes in Aml1-excised leukemia cell. Decreased expression of cell cycle– and apoptosis-related.

Loss of Setdb1 in early B cells leads to impaired B cell development.

TCR signaling is required for exhausted-like TRM cell formation and maintenance. TCR signaling is required for exhausted-like TRM cell formation and maintenance.

All Hematopoietic Stem Cells Engraft in Submyeloablatively Irradiated Mice Katarina Forgacova, Filipp Savvulidi, Ludek Sefc, Jana Linhartova, Emanuel.

Comparison of conventional NSG and hIL-7 expressing NSG humanized mice

Anti-hOX40L treatment prevents aGVHD development in NOG mice transplanted with human PBMCs. NOG mice received human PBMCs (1 × 107) via tail vein. animals.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

ABT-199 efficiently kills primary AML myeloblasts as a single agent.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Engraftment of ROSAKIT D816V-Gluc cells in NSG mice.

Fig. 5 Treatment with BMS (PO BID) protects from wasting and colitis in two SCID mouse models. Treatment with BMS (PO BID) protects from.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Immunohistochemical detection of 8-OHdG by use of the 1F7 monoclonal antibody in oligomer-treated PC3 prostate cancer cells. a, control untreated peripheral.

Leukemic blasts express a “hypoxia signature

GS87 demonstrates efficacy in a circulating AML mouse model system.

coTCRcys-transduced T cells control tumor growth in vivo.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Response of the Idh2R140Q Flt3ITD leukemia model to AG-221 therapy.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

IDO deficiency delays the development of pulmonary metastases.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

SY-1425 induces maturation in RARA-high AML

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Crebbp deficiency accelerates B-cell lymphoma development in mice.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Pdcd4 expression inhibits AP-1 transactivation.

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

PDL192 and inhibit the growth of xenograft tumors.

Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. Treatment with a Ron inhibitor significantly reduces metastatic outgrowth. A,

Cabozantinib causes significant tumor cell elimination in vivo, but modest apoptosis induction in vitro. Cabozantinib causes significant tumor cell elimination.

GCS-100 selectively kills KRAS-addicted lung tumors.

BV6 increases bone metastasis.

Both TKI and EZH2i upregulate H3K27me3 targets, and combined treatment potentiates loss of LSCs. A, summary of global mean mRNA expression changes found.

CPI-444 synergizes with anti–PD-L1 and anti–CTLA-4 treatment.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

AMG 176 exhibits robust single-agent activity in vivo.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Ezh2 inactivation inhibits initiation/progression of CML and establishment of secondary leukemia from existing LICs. A, protocol for induction of Ezh2.

Presentation transcript:

Inhibition of MCL1 reduces AML in an in vivo murine model. Inhibition of MCL1 reduces AML in an in vivo murine model. A, NSGS mice were engrafted with MV-4-11 human leukemia cells and were then treated with either vehicle (n = 6) or 10 (n = 5), 25 (n = 5), or 75 (n = 5) mg/kg of VU661013. Peripheral blood, bone marrow (BM), and spleen (SPL) were harvested for tricompartmental chimerism analysis. A nonparametric, unpaired, two-tailed t test was used to calculate significance. B, IHC of femurs and spleen (20×) stained with monoclonal antibody for hCD45 reveal AML cells left within the bone marrow and spleen of experimental mice at each dose level. C, Ratio of spleen to total body weight measurements from above-mentioned experiments. D, Kaplan–Meier analysis. Statistical significance was calculated using log-rank (Mantel–Cox) test (P = 0.001; n = 5 per arm). Haley E. Ramsey et al. Cancer Discov 2018;8:1566-1581 ©2018 by American Association for Cancer Research